Posted by Michael Wonder on 13 Jul 2024
AbbVie submits regulatory applications to FDA and EMA for upadacitinib (Rinvoq) in giant cell arteritis
12 July 2024 - Submissions are supported by the Phase 3 SELECT-GCA study demonstrating upadacitinib 15 mg with a 26 week steroid taper regimen achieved the primary endpoint of sustained remission from week 12 through week 52.
AbbVie today announced that it has submitted applications for a new indication to the US FDA and EMA for upadacitinib (Rinvoq 15 mg, once daily) for the treatment of adult patients with giant cell arteritis.
